Caribou Biosciences, Inc. (CRBU): Capital Expenditures
$1.36M
Year ended 2025-12-31
-40.5%
3-year compound annual growth
+33.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.36M | -72.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $4.88M | -58.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $11.61M | +79.9% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $6.45M | +204.3% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $2.12M | +569.1% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $317.0K | -64.1% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $884.0K | n/a | 2022-03-21, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $1.36M | -72.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $4.41M | +15.2% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $293.5K | +999.2% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $738.0K | +97.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $410.0K | -79.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $5.95M | +715.5% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $827.0K | +76.7% |
Compare CRBU, TCRX, ACOG, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗